Analogous to 177Lu-PSMA-RLT, the therapeutic goal of 225Ac-PSMA-RLT is to inhibit/slow down the growth of prostate cancer cells, e.g., in bone and soft tissue metastases. This evidence concerns the gene FOLH1 and prostate carcinoma.